PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

191 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
81.
Opatz, S.* et al.: Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood 122, 1761-1769 (2013)
82.
Alves, C.C. et al.: Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 119, 4224-4227 (2012)
83.
Greif, P.A. et al.: GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 120, 395-403 (2012)
84.
Huang, J.* et al.: Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 120, 4873-4881 (2012)
85.
Metzeler, K.H.* et al.: High expression of Lymphoid Enhancer-binding Factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 120, 2118-2126 (2012)
86.
Schlitzer, A.* et al.: Tissue-specific differentiation of a circulating CCR9- pDC-like common dendritic cell precursor. Blood 119, 6063-6071 (2012)
87.
Schneider, F.* et al.: The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood 119, 4383-4386 (2012)
88.
Spranger, S. et al.: TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood 119, 3440-3449 (2012)
89.
Thomas, M.F.* et al.: Eri1 regulates microRNA homeostasis and mouse lymphocyte development and anti-viral function. Blood 120, 130-142 (2012)
90.
de Andrés-Aguayo, L.* et al.: Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice. Blood 118, 554-564 (2011)
91.
Ehrhardt, H. et al.: Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood 118, 6123-6131 (2011)
92.
Hammerschmidt, W.: What keeps the power on in lymphomas? (Comment on Vereide and Sudgen, page 1977) Blood 117, 1777-1778 (2011)
93.
Hampel, F. et al.: CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling. Blood 118, 6321-6331 (2011)
94.
Istvanffy, R.* et al.: Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. Blood 118, 2712-2722 (2011)
95.
Koestner, W.* et al.: PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8⁺ T cells. Blood 117, 1030-1041 (2011)
96.
Lückerath, K.* et al.: Immune modulation by Fas ligand reverse signaling: Lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. Blood 117, 519-529 (2011)
97.
Schlitzer, A.* et al.: Identification of CCR9- murine plasmacytoid DC precursors with plasticity to differentiate into conventional DCs. Blood 117, 6562-6570 (2011)
98.
Turchinovich, G.* et al.: Programming of marginal zone B-cell fate by basic Krüppel-like factor (BKLF/KLF3). Blood 117, 3780-3792 (2011)
99.
Albert, M.H.* et al.: X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options. Blood 115, 3231-3238 (2010)
100.
Ingersoll, M.A.* et al.: Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115, 10-19 (2010)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮